About a year after launching with the help of Atlas Venture and Johnson & Johnson's Massachusetts biotech incubator, Cambridge's Rodin Therapeutics is setting out with $12.9 million in Series A cash and a plan to apply some cutting-edge science to common central nervous system disorders.
After seeding a fledgling scientific effort focused on the biologic implications of regulating proteins, Third Rock and The Column Group are throwing $25 million behind a startup biotech--Nurix--that hopes to blaze a new path in small molecule drug development.
You can add another upstart to the swelling list of gene therapy biotechs hitting the industry radar around the world. Sofinnova stepped in to lead the $22 million A round for Paris-based Lysogene, which is already in the clinic with a new therapy for rare cases of Sanfilippo syndrome, with plans to branch out into other neurodegenerative conditions.
Just months after inking a $246 million development deal with Baxter for a biosimilar of Enbrel, Redwood City, CA-based Coherus has rounded up a whopping $55 million C round, including cash from KKR.
The rise of omics data in R&D has increased the overlap between biotech and Silicon Valley-style tech startups, with Flatiron Health's recent $130 million round making it a standout example. This week, SolveBio took its first steps on the path established by Flatiron by raising cash from the co-founder of Paypal other other leading tech investors.
Boston startup Gelesis has picked up $12 million in venture funding, cash that'll support its novel approach to obesity treatment: a pill that disperses expanding particles in the gut to make patients feel full.
Cambridge, U.K.'s Kymab touts its drug development platform as an ideal way to spotlight new antibodies, and some bright minds would seem to agree, as the Wellcome Trust and Bill and Melinda Gates Foundation have teamed up on a $40 million round for the biotech.
With $45 million in venture commitments under its belt, Proteon is set to roll into a late-stage study for its top candidate, with no need for Big Pharma help.
ZS Pharma is executing a familiar biotech gambit. The Texas-based biotech raised $55 million from some top venture groups just a few weeks ago, and now it's formally moving ahead with an $86 million IPO.
Promising to use its technology to enhance the efficacy and safety of currently approved Alzheimer's drugs, Chase Pharmaceuticals says it has now added $21 million in new venture cash.